Please login to the form below

Not currently logged in
Email:
Password:

Symtuza

This page shows the latest Symtuza news and features for those working in and with pharma, biotech and healthcare.

Positive trial results for Janssen’s Symtuza boosts its HIV credentials

Positive trial results for Janssen’s Symtuza boosts its HIV credentials

The STR provided ‘effective’and ‘durable’viral suppression. Janssen’s darunavir-based single tablet regimen (STR) Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) showed a positive outcome in the treatment of HIV

Latest news

  • Janssen wins European approval for Symtuza Janssen wins European approval for Symtuza

    Janssen wins European approval for Symtuza. European Commission approves the drug to treat HIV-1. ... The European Commission (EC) has approved Janssen’s Symtuza (darunavir-STR) to treat adults with human immunodeficiency virus type 1 (HIV-1).

  • CHMP backs three immuno-oncology drugs for solid tumours CHMP backs three immuno-oncology drugs for solid tumours

    Away from the cancer field, Johnson &Johnson's Janssen pharma unit got a positive opinion for Symtuza, the first complete, single-tablet HIV regimen based on its big-selling protease inhibitor

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics